Join Growin Stock Community!

Omniab, inc.OABIW.US Overview

US StockHealthcare
(No presentation for OABIW)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

OABIW AI Insights

OABIW Overall Performance

OABIW AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

OABIW Recent Performance

-

Omniab, inc.

-3.61%

Avg of Sector

-2.16%

S&P500

OABIW PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

OABIW Key Information

OABIW Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

OABIW Profile

OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.

Price of OABIW

OABIW FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

OABIW Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.44
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
76.55%
Net Margin
-301.83%
Revenue Growth (YoY)
3.36%
Profit Growth (YoY)
4.35%
3-Year Revenue Growth
-31.32%
3-Year Profit Growth
-7.69%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.44
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
76.55%
Net Margin
-301.83%
Revenue Growth (YoY)
3.36%
Profit Growth (YoY)
4.35%
3-Year Revenue Growth
-31.32%
3-Year Profit Growth
-7.69%
  • When is OABIW's latest earnings report released?

    The most recent financial report for Omniab, inc. (OABIW) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating OABIW's short-term business performance and financial health. For the latest updates on OABIW's earnings releases, visit this page regularly.

  • What is the operating profit of OABIW?

    According to the latest financial report, Omniab, inc. (OABIW) reported an Operating Profit of -18.16M with an Operating Margin of -811.26% this period, representing a growth of 8.1% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is OABIW's revenue growth?

    In the latest financial report, Omniab, inc. (OABIW) announced revenue of 2.24M, with a Year-Over-Year growth rate of -46.33%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does OABIW have?

    At the end of the period, Omniab, inc. (OABIW) held Total Cash and Cash Equivalents of 28.54M, accounting for 0.09 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does OABIW go with three margins increasing?

    In the latest report, Omniab, inc. (OABIW) did not achieve the “three margins increasing” benchmark, with a gross margin of 98.7%%, operating margin of -810.18%%, and net margin of -738.05%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess OABIW's profit trajectory and future growth potential.

  • Is OABIW's EPS continuing to grow?

    According to the past four quarterly reports, Omniab, inc. (OABIW)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.14. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of OABIW?

    Omniab, inc. (OABIW)'s Free Cash Flow (FCF) for the period is -9.95M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 47.77% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of OABIW?

    The latest valuation data shows Omniab, inc. (OABIW) has a Price-To-Earnings (PE) ratio of -2.78 and a Price/Earnings-To-Growth (PEG) ratio of 0.42. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.